Basal Cell Carcinoma (BCC)
Basal cell carcinoma (BCC) is the most common skin cancer in humans, accounting for over 70–80% of all non-melanoma skin cancers (NMSC). It arises from basaloid cells in the basal layer of the epidermis or the outer root sheath of hair follicles. Although BCC grows relatively slowly and very rarely spreads to distant sites (less than 0.1%), it can be highly destructive locally. Without diagnosis and complete treatment, the tumor can burrow into deeper structures such as subcutaneous fat, cartilage, muscle, periosteum and the skull, seriously disfiguring the face and threatening vital sensory functions.
At Haute-Derma, we offer complete BCC care: high-resolution dermoscopy, accurate histopathological biopsy, Mohs micrographic surgery with full margin control, and specialist cosmetic reconstruction. Our aim is to remove the tumor completely, preserve as much healthy tissue as possible and restore the patient's confidence.
Pathogenesis and the Hedgehog Signaling Pathway
- Molecular mechanism: Accumulated genetic mutations from UV light (especially UVB) are the root cause of BCC. Abnormal activation of the Hedgehog signaling pathway, mainly through loss-of-function mutations in the tumor suppressor gene PTCH1 (Patched 1) or gain-of-function mutations in SMO (Smoothened), drives uncontrolled growth of basaloid progenitor cells.
- Varied clinical forms:
- Nodular BCC: The most common type (60%). A dome-shaped, skin-pink or shiny pearly gray bump (pearly papule) with branching surface vessels (arborizing telangiectasia); the center may dip inward or ulcerate (rodent ulcer).
- Superficial BCC: A light red, well-defined patch with fine scale, usually on the trunk, and easily mistaken for psoriasis or Bowen's disease.
- Infiltrative / morpheaform BCC: The most dangerous type. It looks like a firm, ivory-white or pale yellow scar with very indistinct clinical borders and a strong tendency to spread silently beneath healthy-looking skin.
- Pigmented BCC: Contains brown-black flecks of melanin and is easily confused with melanoma.
Histopathology
- Basaloid aggregates: Nests, lobules or strands of epithelial cells with small, dark-staining (hyperchromatic) nuclei and scant cytoplasm, tightly packed in the dermis.
- Peripheral palisading: The outermost cells of each tumor nest line up side by side like a fence, perpendicular to the tumor edge. This is the most characteristic microscopic feature of BCC.
- Stromal retraction (clefting): Mucin change in the surrounding stroma creates artificial clefts that separate the tumor from the normal dermis.
- Risk classification based on histology:
- Low risk: nodular, superficial and adenoid types.
- High risk: infiltrative, micronodular, morpheaform and basosquamous (metatypical) types. These tend to invade deeply, have hard-to-define margins and recur more often.
Differential Diagnosis and Immunohistochemistry (IHC)
| Condition | Distinguishing Microscopic Features | Immunohistochemical (IHC) Markers |
|---|---|---|
| Basal cell carcinoma (BCC) | Basaloid nests with peripheral palisading and stromal retraction; no intercellular bridges. | BerEP4 strongly and diffusely positive; Bcl-2 strongly positive; CD10 positive in tumor cells; CD34 negative in the surrounding stroma. |
| Cutaneous squamous cell carcinoma (cSCC) | Atypical keratinocytes with intercellular bridges and keratinization; no peripheral palisading. | BerEP4 negative; p63/p40 strongly positive; EMA positive; adipophilin negative. |
| Trichoblastoma | Benign tumor surrounded by mature, fibroblast-rich fibrous stroma; no obvious stromal retraction clefts. | CD34 strongly positive in the peritumoral stroma; BerEP4 positive; CK20 positive in Merkel cells. |
| Trichoepithelioma | Papillary mesenchymal bodies, small horn cysts; no atypia or malignant mitoses. | CD34 positive in the stroma; CK20 positive in scattered Merkel cells. |
Our Approach to Treating Basal Cell Carcinoma
Guided by the twin goals of complete cure and a good cosmetic result, Haute-Derma manages basal cell carcinoma in several layers:
- Detailed dermoscopy and histological assessment: We accurately determine the size, histological subtype and borders of the lesion before treatment.
- Mohs micrographic surgery (MMS) as the preferred option: The first choice for examining 100% of the surgical margin under the microscope, removing all cancer cells while sparing as much healthy facial tissue as possible.
- Treatment tailored to risk group: We clearly separate low-risk from high-risk (infiltrative/morpheaform) tumors to choose the right surgical margins.
- Cosmetic reconstruction and full recovery: Fine microsurgical suturing, reconstructive skin flaps and a post-operative scar management plan help restore the face's natural contours.
How Basal Cell Carcinoma Is Diagnosed at Haute-Derma
To reach an accurate diagnosis and recommend evidence-based treatment, Haute-Derma follows a rigorous 4-step process:
- Clinical examination and high-resolution dermoscopy: We look for characteristic features such as arborizing vessels, blue-gray ovoid nests, leaf-like structures and spoke-wheel areas.
- Histopathological biopsy (punch or shave): A sample deep enough to identify the exact histological subtype (nodular, superficial or high-risk infiltrative).
- Differential immunohistochemistry (IHC): In histologically complex cases, a panel of BerEP4, CD34, Bcl-2 and p40 helps clearly separate BCC from cutaneous squamous cell carcinoma (cSCC) or benign adnexal tumors.
- Assessing invasion and the tumor base: For large tumors or those in high-risk locations (the H-zone of the face: eyes, nose, ears, lips), we evaluate how deeply they extend into subcutaneous fat, deep fascia or periosteum.
Specialist Treatment at Haute-Derma
Our treatment aims to remove the tumor completely, keep the recurrence rate as low as possible and restore the patient's appearance:
- Mohs Micrographic Surgery (MMS):
- The gold standard for BCC on the face (H-zone), high-risk histological subtypes (infiltrative/morpheaform) and recurrent BCC.
- The surgeon removes the tumor and prepares frozen sections to examine 100% of the margin (both edges and base) during the operation, repeating until no cancer cells remain (R0 margin). Cure rates reach 99%.
- Standard Excision:
- Used for small, low-risk BCCs (nodular, superficial) on the trunk, arms or legs.
- A safety margin of 4–6 mm beyond the visible edge is taken to ensure clear margins.
- Superficial Treatments (for Extensive Superficial BCC):
- Superpulsed CO2 laser ablation / curettage and electrodesiccation: For superficial BCC in sites where excision is not feasible.
- Topical immune modulator (imiquimod 5%): For extensive superficial BCC when the patient declines surgery or surgery is contraindicated.
- Targeted Therapy (Hedgehog Pathway Inhibitors: Vismodegib / Sonidegib):
- We provide counseling and coordinate referral for severe locally advanced BCC that cannot be treated with surgery or radiotherapy, or for metastatic BCC (extremely rare).
- Cosmetic Reconstruction and Post-Operative Care:
- Local skin flaps and autologous skin grafts, closed with fine cosmetic microsurgical sutures.
- LED light therapy to support tissue repair and dedicated scar management after suture removal.
